Skip to content
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Breast Surgery · Breast Cancer

What to Expect: Sentinel Lymph Node Biopsy for Breast Cancer

At a Glance

For upper-outer breast cancer, sentinel lymph node biopsy uses a tracer, blue dye, or both to find the first underarm nodes at risk. Pathology shows whether cancer is in the nodes and helps determine whether more surgery, radiation, chemotherapy, hormone therapy, or targeted treatment is needed.

A sentinel lymph node biopsy (SLNB) is a surgical procedure that removes and checks the first lymph nodes your breast cancer is most likely to spread to [1]. By using a radioactive tracer or blue dye, your surgical team can locate these specific “sentinel” nodes in your armpit [1][2]. If these nodes are free of cancer, it is highly likely the rest of your lymph nodes are too, usually sparing you from a more extensive surgery [3]. If cancer cells are found, the size of the cancer deposits—whether they are tiny clusters or larger masses—will help your multidisciplinary care team determine if you need additional treatments like radiation, targeted therapy, or chemotherapy, and in some selected cases, further surgery [4][5].

How the Procedure Works

Mapping with Tracer and Dye

Before or during surgery, your care team will inject a small amount of a radioactive tracer (often technetium-99m), a blue dye, or both into your breast [1][2]. These substances follow the same lymphatic drainage pathways that cancer cells would take. Having an upper-outer quadrant tumor means the cancer’s physical location is an anatomic area close to the armpit, but this proximity does not automatically mean the cancer has spread to the lymph nodes. Your surgeon may adjust the injection site (such as near the nipple) so the radioactive tracer in the breast doesn’t overshadow the signal from the nearby lymph nodes (a mapping phenomenon called “shine-through”) [6][7].

Locating and Removing the Nodes

During the breast operation, the surgeon uses a handheld tool called a gamma probe to detect the radioactive tracer and looks visually for nodes stained blue [1][8]. They will make a small incision in your armpit and carefully remove these sentinel nodes, which is often one to a few nodes, but the exact number varies [9].

Pathology Examination

The removed nodes are sent to a pathologist who examines them under a microscope [9]. Sometimes, a rapid initial check is done while you are still in surgery, but this varies by institution and is less sensitive than the final examination. A more thorough evaluation of permanent tissue sections takes several days [10]. Pathologists often use immunohistochemistry, a technique using antibody-based stains to identify tiny cancer cells that conventional stains might miss [11]. This is why microscopic amounts of cancer are sometimes discovered days after the surgery even if the initial rapid check looked clear [12][13]. Waiting for these final results can be stressful; you may want to ask for a specific follow-up appointment to discuss the complete pathology report.

Side Effects and Recovery

Because a sentinel lymph node biopsy removes only a few nodes, the physical recovery is much easier than a full axillary lymph node dissection (the surgical removal of many lymph nodes). However, you should be aware of a few temporary or lasting effects:

  • Discoloration: The blue dye can turn your urine blue or green for a few days and leave a temporary blue tint or permanent small “tattoo” mark on your breast skin [14][15].
  • Numbness and Pain: It is common to experience some bruising, temporary shoulder stiffness, numbness, tingling (paresthesia), or mild pain in the armpit or back of the arm [16][17].
  • Lymphedema: The risk of developing lymphedema, which is chronic arm swelling caused by fluid buildup, is reduced after a sentinel biopsy but is not zero [1]. Research estimates lymphedema occurs in fewer than 5% of patients after a sentinel biopsy, compared to up to 25% of patients who undergo a full dissection, though individual risk varies based on body weight, radiation, and the number of nodes removed [18]. Watch for symptoms like new arm swelling, heaviness, tightness, or changes in hand size.
  • Other Complications: Like any surgery, there is a small risk of bleeding, a fluid collection (seroma), or infection [19]. Contact your care team if you experience a fever, worsening redness, drainage, rapidly increasing swelling, or uncontrolled pain. Very rarely, the blue dye can cause a serious allergic reaction; seek urgent medical help if you experience breathing difficulty, facial swelling, or widespread hives after the procedure [14].

Understanding Your Results

Your pathology report will detail exactly what was found in the nodes. The amount of cancer is categorized by precise size boundaries:

  • Negative Nodes: No cancer cells were found.
  • Isolated Tumor Cells (ITCs): Extremely tiny clusters of cancer cells, measuring up to and including 0.2 mm0.2 \text{ mm} or containing no more than 200 cells [20][21]. Pathology reports often label this as pN0(i+), distinguishing it from larger positive deposits.
  • Micrometastasis: A deposit of cancer cells measuring greater than 0.2 mm0.2 \text{ mm} up to and including 2.0 mm2.0 \text{ mm} [20][22].
  • Macrometastasis: A larger cluster of cancer cells measuring greater than 2.0 mm2.0 \text{ mm} [20][22].

How Your Results Shape Your Treatment

The results of your biopsy directly influence your next steps, particularly whether you can safely skip further lymph node surgery. These guidelines are primarily for patients with early-stage, clinically node-negative breast cancer.

If the Results are Negative

If your sentinel nodes are clear, your surgical team usually will not need to remove any more lymph nodes [3].

If ITCs or Micrometastases are Found

Finding very small amounts of cancer may not require further surgery in selected circumstances [5]. Cancer cells detected in a nearby lymph node help estimate recurrence risk, but the significance of a very small deposit differs from that of a larger metastasis. Research shows that leaving the remaining lymph nodes intact and treating the area with your already planned radiation or systemic therapy is generally safe for eligible patients and avoids the complications of a full lymph node dissection [5][23][24].

If Macrometastases are Found

Historically, finding macrometastases meant you automatically needed a full axillary lymph node dissection. Today, decisions are highly individualized. If you have early-stage, clinically node-negative cancer, you may be eligible to skip a full dissection if you only have 1 or 2 nodes with macrometastasis and are undergoing a lumpectomy (breast-conserving surgery) followed by whole-breast radiation [5][25]. Even for selected patients having a mastectomy (complete breast removal), clinical guidelines now allow some to receive targeted regional-nodal radiation instead of removing more nodes [5]. Your surgeon and radiation oncologist will determine if you meet the specific criteria to safely avoid further surgery.

Impact on Medications

Nodal status is only one of several factors—along with your tumor’s size, grade, hormone receptor status, and genomic test results—that shape your systemic (whole-body) treatment plan [4]. A positive node does not automatically mean you need chemotherapy. However, depending on your cancer’s complete biology, positive nodes might make you eligible for specific chemotherapy drugs, hormone therapies, or targeted treatments like CDK4/6 inhibitors (medications that help stop cancer cells from multiplying) to help reduce the risk of the cancer returning [4][26].

Common questions in this guide

Why is a sentinel lymph node biopsy recommended for breast cancer?
The procedure checks the first lymph nodes in the armpit that breast cancer is most likely to reach. If they are clear, many patients can avoid removal of more lymph nodes; if cancer is found, the result helps guide surgery, radiation, and whole-body treatment.
Does an upper-outer breast tumor automatically mean cancer has reached the lymph nodes?
No. A tumor in the upper-outer quadrant is close to the armpit anatomically, but that location alone does not show that cancer has spread. Sentinel node mapping and pathology are used to evaluate the nodes.
What happens during sentinel node mapping and surgery?
A small amount of radioactive tracer, blue dye, or both is injected into the breast. The surgeon uses a detector and the blue color to find and remove usually one to a few sentinel nodes through a small armpit incision. The injection site may be adjusted for an upper-outer tumor so the breast signal does not obscure nearby nodes.
Why can the final sentinel node results take several days?
A rapid check may be done during surgery, but it is not as sensitive as the final examination. Permanent tissue sections and special stains may identify very small cancer deposits, so the complete pathology report often takes several days.
How are isolated tumor cells, micrometastases, and macrometastases different?
Isolated tumor cells are tiny deposits up to 0.2 mm, micrometastases are larger than 0.2 mm through 2 mm, and macrometastases are larger than 2 mm. These categories help your team estimate nodal involvement and decide whether additional surgery or other treatment is appropriate.
Does a positive sentinel node always mean I need more lymph node surgery?
Not necessarily. Patients with early-stage, clinically node-negative cancer may be able to avoid full axillary dissection in selected situations, including some people with one or two involved nodes who have lumpectomy and whole-breast radiation; some mastectomy patients may receive regional-nodal radiation instead. Eligibility depends on the number and size of deposits, surgery type, radiation plan, and other clinical details.
What is the risk of lymphedema after sentinel node biopsy?
The risk is lower after sentinel biopsy than after full axillary dissection, but it is not zero. Research cited on this page estimates lymphedema in fewer than 5% of patients after sentinel biopsy, although risk varies with factors such as higher body weight, radiation, and the number of nodes removed. Report new arm swelling, heaviness, tightness, or hand-size changes to your care team.

Get notified when new evidence is published on female breast upper-outer quadrant cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    The Past, Present, and Future of Sentinel Lymph Node Biopsy in Breast Cancer.

    Stanczyk M, Cheung TC, Lang JE

    Annals of surgical oncology 2026; (33(9)):8225-8237 doi:10.1245/s10434-026-19672-4.

    PMID: 42213262
  2. 2

    Sentinel Lymph Node Mapping in Breast Cancer Patients Through Fluorescent Imaging Using Indocyanine Green: The INFLUENCE Trial.

    Bargon CA, Huibers A, Young-Afat DA, et al.

    Annals of surgery 2022; (276(5)):913-920 doi:10.1097/SLA.0000000000005633.

    PMID: 35894448
  3. 3

    Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

    Lyman GH, Somerfield MR, Bosserman LD, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(5)):561-564 doi:10.1200/JCO.2016.71.0947.

    PMID: 27937089
  4. 4

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Andre F, Ismaila N, Allison KH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

    PMID: 35439025
  5. 5

    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Park KU, Somerfield MR, Anne N, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

    PMID: 40209128
  6. 6

    Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer.

    Ho CC, Chen YH, Liu SH, et al.

    Tzu chi medical journal 2019; (31(3)):163-168 doi:10.4103/tcmj.tcmj_88_18.

    PMID: 31258292
  7. 7

    Efficacy of Periareolar Versus Peritumoral Injection of TC99-Labelled Sulphur Colloid and Methylene Blue Dye for Detection of Sentinel Lymph Node in Patients with Early Breast Cancer: a Comparative Study.

    Malhotra C, Pawar R, Patni S, et al.

    Indian journal of surgical oncology 2021; (12(1)):119-123 doi:10.1007/s13193-020-01235-y.

    PMID: 33814841
  8. 8

    Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study.

    Guo J, Yang H, Wang S, et al.

    World journal of surgical oncology 2017; (15(1)):196 doi:10.1186/s12957-017-1264-7.

    PMID: 29096643
  9. 9

    Comparison between hemosiderin and Technetium-99 in sentinel lymph node biopsy in human breast cancer.

    Vasques PH, Alves MM, Aquino RG, et al.

    Acta cirurgica brasileira 2015; (30(11)):785-90.

    PMID: 26647799
  10. 10

    Is Sentinel Lymph Node Biopsy a Viable Alternative to Axillary Lymph Node Dissection in Breast Carcinoma Patients Who Have Received Neo-Adjuvant Chemotherapy?

    Sulthana R, Singh A

    Cureus 2024; (16(1)):e52698 doi:10.7759/cureus.52698.

    PMID: 38384601
  11. 11

    Application of immunohistochemistry for detection of metastases in sentinel lymph nodes of non-advanced breast cancer patients.

    Nowikiewicz T, Śrutek E, Zegarski W

    Polish journal of pathology : official journal of the Polish Society of Pathologists 2015; (66(1)):22-9 doi:10.5114/pjp.2015.51149.

    PMID: 26017876
  12. 12

    Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift.

    Maguire A, Brogi E

    Archives of pathology & laboratory medicine 2016; (140(8)):791-8 doi:10.5858/arpa.2015-0140-RA.

    PMID: 27472237
  13. 13

    False negative rate for intraoperative sentinel lymph node frozen section in patients with breast cancer: a retrospective analysis of patients in a single Asian institution.

    Wong J, Yong WS, Thike AA, et al.

    Journal of clinical pathology 2015; (68(7)):536-40 doi:10.1136/jclinpath-2014-202799.

    PMID: 25855801
  14. 14

    Meta-analysis Comparing Fluorescence Imaging with Radioisotope and Blue Dye-Guided Sentinel Node Identification for Breast Cancer Surgery.

    Kedrzycki MS, Leiloglou M, Ashrafian H, et al.

    Annals of surgical oncology 2021; (28(7)):3738-3748 doi:10.1245/s10434-020-09288-7.

    PMID: 33156466
  15. 15

    The Use of Periareolar Topical Lidocaine Jelly After Needle Localization May Reduce Pain of Subsequent Lymphoscintigraphy.

    Virk J, Smock B, Nadeem M, et al.

    Cureus 2020; (12(4)):e7861 doi:10.7759/cureus.7861.

    PMID: 32483511
  16. 16

    Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: A meta-analysis.

    Li CZ, Zhang P, Li RW, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2015; (41(8)):958-66.

    PMID: 26054706
  17. 17

    Sentinel Lymph Node Biopsy in Early Breast Cancer Using Methylene Blue Dye Alone: a Safe, Simple, and Cost-Effective Procedure in Resource-Constrained Settings.

    Devarakonda S, Thomas SS, Sen S, et al.

    Indian journal of surgical oncology 2021; (12(1)):210-217 doi:10.1007/s13193-020-01273-6.

    PMID: 33814855
  18. 18

    Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.

    Li J, Jia S, Zhang W, et al.

    BMC surgery 2015; (15()):79 doi:10.1186/s12893-015-0067-4.

    PMID: 26123412
  19. 19

    Sentinel Lymph Node Biopsy in Breast Cancer: Indications, Contraindications, and Controversies.

    Manca G, Rubello D, Tardelli E, et al.

    Clinical nuclear medicine 2016; (41(2)):126-33 doi:10.1097/RLU.0000000000000985.

    PMID: 26447368
  20. 20

    Micro- and macro-metastasis in the axillary lymph node: A review.

    Naidoo K, Pinder SE

    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2017; (15(2)):76-82 doi:10.1016/j.surge.2016.07.002.

    PMID: 27498412
  21. 21

    Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆.

    Houvenaeghel G, de Nonneville A, Cohen M, et al.

    ESMO open 2021; (6(3)):100151 doi:10.1016/j.esmoop.2021.100151.

    PMID: 33984674
  22. 22

    Occult metastases in node-negative breast cancer: A Surveillance, Epidemiology, and End Results-based analysis.

    Kimbrough CW, McMasters KM, Quillo A, Ajkay N

    Surgery 2015; (158(2)):494-500.

    PMID: 26032821
  23. 23

    Axillary Recurrence and Survival After Omission of Axillary Lymph Node Dissection in Patients with Breast Cancer and Micrometastases or Isolated Tumor Cells in the Sentinel Node: A Danish National Register Study.

    Korsholm RHR, Kroman N, Tvedskov TF, Munck F

    Annals of surgical oncology 2026; (33(10)):9080-9088 doi:10.1245/s10434-026-20072-x.

    PMID: 42406208
  24. 24

    Pathologic Evaluation and Prognostic Implications of Nodal Micrometastases in Breast Cancer.

    Dutta SW, Volaric A, Morgan JT, et al.

    Seminars in radiation oncology 2019; (29(2)):102-110 doi:10.1016/j.semradonc.2018.11.001.

    PMID: 30827448
  25. 25

    Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.

    de Boniface J, Filtenborg Tvedskov T, Rydén L, et al.

    The New England journal of medicine 2024; (390(13)):1163-1175 doi:10.1056/NEJMoa2313487.

    PMID: 38598571
  26. 26

    Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-World Cohort Analysis.

    Kandzi JD, Englisch A, Boeer B, et al.

    Clinical breast cancer 2026; (26(3)):169-175 doi:10.1016/j.clbc.2025.10.003.

    PMID: 41233220

This page provides informational guidance about sentinel lymph node biopsy for breast cancer and does not constitute medical advice. Your breast surgeon and oncology team should interpret your results and recommend care for your situation.